US FDA Deems Synapse’s Clinical Trials ‘Unacceptable’
Executive Summary
The FDA followed the EMA’s lead and declared Synapse’s trials “unacceptable” forcing drug firms that used CRO’s services to repeat studies to regain therapeutic equivalence ratings.